Antengene

Company Introduction

3D Medicines, Inc. is a clinical-stage biopharmaceutical company with a mission to help people with cancer live longer and better. Envisioning a future when cancer is managed as a chronic disease, 3D Medicines focuses on the development of differentiated next-generation immuno-oncology drugs, helping cancer patients live with prolonged survival time and a better quality of life. 3D Medicines has established a pipeline with both next-generation biological macromolecule and chemotherapeutic small-molecule drugs, as well as a professional team capable of global development, registration and commercialization operation.

MORE

February 2021

In February, 2021, the construction of 3D Medicines’ R&D and Manufacturing Center started in Xuzhou, Jiangsu.

04
04
04
04
04
04
March 2020
October 2020
November 2020
December 2020
January 2021
February 2021
In March, 2020, a partnership with Alphamab and Simcere Pharmaceuticals was formed for the development and commercialization of KN035 in China.
In October, 2020, we received $140 million investment from Simcere Pharmaceuticals, Efung Capital, China Capital Management and other institutions.
In November, 2020, Envafolimab (KN035), the world's first PD-L1 antibody drug given via subcutaneous Injection submitted new drug application for marketing in China.
In December, 2020, the NDA of Envafolimab (KN035) was officially accepted by the NMPA.
In January, 2021, NDA of Envafolimab (KN035) was granted NMPA Priority Review.
In February, 2021, the construction of 3D Medicines’ R&D and Manufacturing Center started in Xuzhou, Jiangsu.

PipelineThe company has established a multi-core collaborative clinical pipeline

Candidate Molecule

Target/
Mechanism

Rights

Preclinical

IND

Phase I

Phase II

Phase Ⅲ

NDA

Marketing

Candidate
Molecule

Target/
Mechanism

Rights

Preclinical

IND

Phase I

Phase Ⅱ

Phase Ⅲ

NDA

Marketing

  • PD-L1
  • Worldwide
  • Pan-cancer (>15 solid tumors including CRC, GC) with MSI-H/dMMR, mono, single-arm, ORR, 2L/3L

  • BTC, combo with chemo vs. chemo, randomized, OS, 1L

  • SC, mono, single-arm, ORR, 2L

  • NSCLC, combo, 1L

  • NSCLC, combo, 2L

  • GC, combo, 1L/2L

  • TMB-H, mono, single-arm, 2L/3L

  • EC, single-arm, combo with lenvatinib, 2L

  • HCC, combo with VEGF inhibitor, 1L/2L

  • RCC, combo with VEGF inhibitor, 1L/2L

  • WT1
  • Greater China
  • Multiple indications

  • AML、MPM、OC、UC

  • GAS6/AXL
  • Greater China
  • NSCLC/OC/Kidney cancer/Pancreatic cancer

  • OC/Kidney cancer/Bladder cancer

  • COX-2 + EP-4
  • Greater China
  • Cancer pain/Chronic pain

  • FGFR1/2/3
  • Worldwide
  • BTC/mUC

  • PSMA+
    targeted TKI
  • Worldwide
  • HCC/Prostate cancer

  • IO therapy for
    multiple
    indications
  • Greater China
  • Multiple indications

  • Next generation
    IO therapy
  • Worldwide
  • Multiple indications

  • Heptavalent
    version of
    3D189
  • Greater China
  • Multiple indications

  • Not disclosed
  • Worldwide
  • Multiple indications

  • Not disclosed
  • Worldwide
  • Multiple indications

Pipeline

  1. KN035
  2. 3D189
  3. 3D229
  4. 3D1001+3D1002
  5. 3D185
  6. 3D011
  7. 3D197
  8. 3D057
  9. 3D059
  10. 3D060
  11. 3D062

CEO QUOTATION

"With the increasing incidence of cancer, cancer has become one of the major public health problems facing mankind; it not only poses a major threat to human health, but also causes a serious burden to economic and social development.

With commitment to the R&D and commercialization of a next-generation of innovative immuno-oncology drugs, 3D Medicines hopes to provide cancer patients across the globe with more effective, more accessible, and more convenient options of next-generation immuno-oncology drugs, thus helping them to live longer and better."


-- John Gong, M.D., Ph.D., Chairman and CEO of 3D Medicines Inc.

MORE

Company News

MORE